In pursuit of this goal, a variety of potential biomarkers have been investigated to assess the efficacy of ICIs across different cancer types, including tumor-infiltrating lymphocytes, programmed cell death ligand (PD-L1) expression, and tumor mutational burden (TMB) [9,10]. Here, CD274 is linked to cancer.